Hikal Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Wed Apr 22 2026

The Hikal share price target 2026 stands at Rs 326-386 as per analyst consensus — implying 21-43% upside from the current CMP of Rs 269. Investors tracking the Hikal share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Hikal (HIKAL) achieves or misses this 12-month target. This article covers every dimension of the Hikal share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Hikal on Univest.

Table of Contents

Hikal Share Price Overview — April 2026

Company	Hikal
NSE Symbol	HIKAL
Sector	Pharma Agro CDMO / API / Specialty
CMP April 2026	Rs 269
52-Week High	Rs 426
52-Week Low	Rs 199
Market Cap	Rs 3,660 Cr
Trailing P/E	22x
Dividend FY26	Rs 3
Promoter Holding	44.5%
FII Holding	8.4%
12M Analyst Target	Rs 326-386
Upside from CMP	21-43%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Hikal price, FII/DII flows and analyst targets on the Univest Screener.

What Is Hikal?

Get Free Analyst Research on Hikal — Tap Here.

Hikal (NSE: HIKAL) is a pharma-agro CDMO — APIs for regulated pharma and active ingredients for global agrochemical companies. FY26-27 recovery driven by new CDMO contracts and agro restocking after FY25 slowdown.

Budget 2026-27 Impact on Pharma Agro CDMO

Budget 2026-27’s agro PLI and pharma API incentives benefit Hikal’s dual pharma-agro CDMO business.

Hikal share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 326	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 326-386	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 199 zone	FY27 miss and extended FII selling

Compare Hikal with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Hikal share price target 2026

1. India Pharma Agro CDMO Sector — Structural Growth Tailwind

India’s Pharma Agro CDMO sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Hikal’s market position within this sector creates compounding runway that underpins the Hikal share price target 2026 consensus of Rs 326-386. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Hikal to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Hikal share price target 2026 consensus of Rs 326-386. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Hikal holds a structural competitive moat in its Pharma Agro CDMO segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Hikal share price target 2026 of Rs 326-386.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Hikal’s borrowing costs and stimulates end-customer demand for Pharma Agro CDMO products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Hikal share price target 2026 of Rs 326-386 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Hikal’s Pharma Agro CDMO business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Hikal share price target 2026 bull case.

Download the Univest iOS App or Android App for live Hikal alerts and SEBI-registered research.

5 Risks That Could Impact the Hikal share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Hikal. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Hikal share price target 2026 consensus of Rs 326-386.

2. Valuation at 22x Requires Consistent Execution

At 22x trailing P/E, Hikal is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Hikal share price target 2026. The Rs 199 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma Agro CDMO

Domestic and global competitors are investing aggressively in Hikal’s Pharma Agro CDMO market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Hikal share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Hikal share price target 2026 of Rs 326-386.

5. FII Selling Risk — 8.4% Institutional Holding

With 8.4% FII ownership, Hikal is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Hikal share price target 2026 analyst consensus of Rs 326-386.

Hikal Bull Case vs Bear Case — Hikal share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	386	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 326-386	High	FY27 in-line earnings, stable macro
Bear Case	Rs 199 zone	Low	FY27 guidance cut, prolonged FII selling

Hikal Share Price Reference Table

NSE Symbol	HIKAL
CMP	Rs 269
52-Week High	Rs 426
52-Week Low	Rs 199
Market Cap	Rs 3,660 Cr
P/E	22x
Promoter	44.5%
FII	8.4%
Dividend FY26	Rs 3
Short-Term Target	Rs 326
12M Target	Rs 326-386
Upside	21-43%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Hikal share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 322	FY27 earnings recovery and Pharma Agro CDMO sector leadership
YES Securities	Buy	Rs 328	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 309	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Hikal.

How to Invest in Hikal — 5 Steps

Step 1: Research on the Univest Screener

Search HIKAL on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Hikal share price target 2026.

Step 2: Identify Entry Level

Hikal at Rs 269 has key support near Rs 199. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Hikal share price target 2026 recovery is Rs 326.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 386 — the bull case for the Hikal share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Hikal share price target 2026.

Conclusion — Hikal share price target 2026

Hikal (HIKAL) at Rs 269 offers 21-43% potential upside to the 12-month Hikal share price target 2026 consensus of Rs 326-386. The bull case to 386 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 199 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Hikal at current levels presents a monitored entry opportunity. For more Hikal share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Hikal share price target 2026

Q: What is Hikal share price target for 2026?

The 12-month Hikal share price target 2026 analyst consensus is Rs 326-386 — implying 21-43% upside from CMP Rs 269. Bull case: 386. Bear case: Rs 199 zone. Track the live Hikal share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Hikal a good buy at Rs 269?

This article does not constitute investment advice. At Rs 269, Hikal offers 21-43% upside to the Hikal share price target 2026 consensus of Rs 326-386. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Hikal 52-week high and low?

Hikal’s 52-week high is Rs 426 and 52-week low is Rs 199. At the current CMP of Rs 269, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Hikal share price target 2026 thesis.

Q: What sector is Hikal (HIKAL) in?

Hikal operates in the Pharma Agro CDMO / API / Specialty sector. India’s Pharma Agro CDMO sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Hikal share price target 2026 bull case.

Q: What are the main risks for the Hikal share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at 22x requiring consistent execution, competition in Pharma Agro CDMO, input cost volatility, and FII selling pressure (8.4% holding). Monitor quarterly earnings closely.

Q: What is Hikal’s market cap?

Hikal has a market cap of Rs 3,660 Cr as of April 2026. At the Hikal share price target 2026 of Rs 326-386, the implied market cap would reflect 21-43% appreciation on the current base.

Q: What is Hikal dividend for FY26?

Hikal’s FY26 dividend is Rs 3. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Hikal share price target 2026 capital appreciation potential.

Q: How to buy Hikal shares?

Buy Hikal (HIKAL) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 199 support zone, and download the Univest App for SEBI-registered research on the Hikal share price target 2026.